Organization | Kanagawa Prefectural Cancer Center

Kanagawa Prefectural Cancer Center Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Yokohama Japan (1986)

Organization Overview

First Clinical Trial

2014

NCT02269475

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Kanagawa Cancer Center | Kanagawa HImawari Clinic

Active Ingredients

Drugs in Phase 3 Trials (6)

docetaxel (taxotere) (1 trial)

eribulin (halaven) (1 trial)

live attenuated influenza virus vaccine (Flumist) (1 trial)

paclitaxel (taxol) (1 trial)

pertuzumab (perjeta) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (1)

s-588410 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 7